Induced pluripotent stem cells (iPSCs) have been increasingly explored by biologists for their therapeutic and medicinal potentials. They can be generated from terminally differentiated somatic cells of a particular patient, thus offering the significant advantage of unlimited self-renewal combined with differentiation into any other type of cell in that body. Although it is possible to derive iPSCs from any source, most are actually derived from human fibroblasts. The cells play an essential role in regenerative medicine as they exhibit embryonic stem cell (ESC) characteristics without the ethical concerns surrounding ESC usage. So far, these have been used to derive immune-matched ovarian, heart, pancreas, and normal-tissue organoids for potential transplantation into patients or as platforms for drug screening. Researchers are starting to use such cells and organoids for personalized drug development and disease modeling.
What are the main incentives driving scientists to work with iPSCs in contemporary science?
Currently, accelerating iPSC-related technologies have brought broad interest in both basic and applied research; however, its clinic practice application is relatively limited since the supply of iPSC organoids is insufficient for patient transplantation or drug screening. Improving the efficiency of generating iPSCs and yield from iPSC-derived organoids will lead to shorter lead times with better interpretation of drug activity toward breakthroughs facilitating their incorporation within therapeutic pipelines.
How do induced pluripotent stem cells come about and what do they do?
Researchers can induce somatic cells to revert back into a pluripotent state by expressing factors associated with pluripotency, resulting in induced pluripotent stem cells (iPSCs). These closely mimic the transcriptomic profile and epigenetic state of embryonic stem cells (ESCs), differentiate into multiple lineages while retaining self-renewability in undifferentiated states. These topics and technologies guide the reprogramming of somatic cells toward a more tolerant and plastic state.
Induced pluripotent stem cells represent an extraordinary breakthrough in stem cell biology as well as regenerative medicine with great potential for clinical application. There is a substantial number of research articles on iPSCs that continue to be published in Nature, Science, and other top journals in related fields. The number of records about iPSCs on PubMed—including primary research articles, reviews, and clinical reports—grew rapidly following the first publication from Yamanaka's group regarding generation of iPSCs in 2006.
What are the main objectives of current iPSC stem cell research?
Current iPSC research focuses mainly on four objectives: New approaches to regenerative therapies, generation of patient-specific stem cells for personalized medicine, disease modeling for better understanding of mechanisms and their progression, and acceleration of drug development, particularly against rare diseases. iPSC studies in these four areas are now leading to innovative discoveries and applications. Regenerative approaches seek to determine if any of the many iPSC-derived cells can functionally repair or replace tissues damaged by injury or disease toward the restoration of health. This is pursued mainly through two complementary strategies. First, cell-based therapies involve the transplantation of the requisite cells – ideally these would be banked off-the-shelf products available to any patient. Second, tissue engineering is an indirect approach that uses iPSCs to build bioengineered tissues that can then be used in in vivo implant or testing studies. iPSCs may permit the use of such engineered tissues as transplantation targets to stimulate embryonic development for whole-organ regeneration or allow in vivo drug testing.
Why is growing in clinics and labs the significance of importance of iPSCs in stem cell research?
In clinics and laboratories, the significance of importance of iPSCs in stem cell research is on the rise for three main reasons. First, research on iPSCs has direct implications for regenerative medicine through cellular replacement therapy for building or repairing tissues to counteract degeneration due to gradual loss-of-function in specific cell populations. New strategies are being developed toward treating diseases of the eye and ear, brain, heart, pancreas, as well as degenerative musculoskeletal disorders. Second, iPSCs enable personalized medicine since, instead of universal treatments, patient-specific cells and tissues can be derived from iPSCs directly for drug testing. Such cells and tissues permit testing compounds with a match to the patient, thereby enhancing the probability of success in clinical trials. Thirdly, this system is viewed as an extremely valuable tool for human disease modeling-the study about conditions that arise within , impact on , or uniquely manifest within humans has very limited scope because animal models often do not translate. Disease modeling using cells from patients related to pathology might greatly improve mechanism understanding plus help discover novel treatment compounds. Therefore, even though cell-replacement therapy's goal dominates regenerative medicine pursuit, it does not constitute all possible pathways open for iPSC research hence, this field could be recognized without such approaches becoming mainstream.
The iPSC technology is not something one can call a total success even if it has the promise to change the field of regenerative medicine and personalized healthcare. The possible use in therapy is big, the excitement very high, and what people expect from it is often unreal. So far, it has not been possible to take results from animal studies and use them in humans to give any real help to patients. However, iPSC technology has become a very useful tool for the drug industry. It offers a strong base for finding new treatments for diseases related to the central nervous system, heart problems, diabetes, and other illnesses where proteins come together or fold wrong. Also, with iPSCs comes a new market that focuses on making and selling disease-specific cell lines for drug finding. This market also gives a very good way to test how safe pharmaceutical compounds are.
How do iPSC regenerative medicine approaches help patients?
Induced pluripotent stem cells (iPSCs) are like embryonic stem cells in terms of regenerative medicine approaches. Patients who suffer from trauma, disease, and degeneration can benefit from creating mature cell phenotypes for damaged tissue or organs. Immune rejection should be minimized or eliminated; autologous iPSCs will solve this problem since they come from the recipient themselves. Isogenic iPSCs also fulfill this requirement because they do not have recognized mutations in the patient's genome and can produce allogeneic progeny from donors without HLA matching.
iPSCs can generate cell types from any of the germ layers in the human body, and much work is going into creating resource banks of iPSC-derived cell types for regenerative medicine that are standardized as well as produced in large quantities. One major preclinical hurdle is deriving an efficient mature cell type safe enough for transplantation; hence, strategies have been developed to generate β cells abundantly from human iPSCs. In type 1 diabetes patients, adequate β cell mass transplantation restores normoglycemia avoiding diabetic complications; however, current shortages make this therapeutic option highly demanding since available donors pose risks due to HLA mismatches. Yet patient-specific β cell generation may provide a personalized solution for this ailment.
What role does personalized medicine with iPSCs play in treatment plans?
Studies typically discuss the future potential of iPSCs and their properties. Patients with genetically determined or inherited diseases have the gene alteration that is responsible for the alteration of the tissue observed. There may be an asymptomatic phase, but the altered gene will eventually express itself in the patient. The cellular mechanisms of the disease can never be investigated in the individual’s own tissue or organ. However, iPSCs can be developed from easily accessible tissue (usually blood) and reprogrammed to pluripotency. These iPSCs could then be differentiated toward the specific cell type that is damaged in the individual. Subsequently, the pathophysiology of the specific disease can be analyzed in vitro. This type of investigation has been carried out for several diseases such as Duchenne muscular dystrophy, Alzheimer’s, Huntington’s, Amyotropic Sclerosis, and others. Modeling Alzheimer’s disease using iPSCs enables mapping and exploring cellular and molecular pathways, including Aβ aggregation, Tau pathology, mitochondrial function as well as reactive gliosis, which includes hyperactivity within astrocytes plus excessive activation of microglia.
Finally, an analysis of cellular pathophysiology provides a deep understanding of the disease and can also serve as a platform for high-throughput drug screening for individual patients. Moreover, the cell type used from the patient is readily available; thus, disease modeling using iPSCs offers a powerful tool in personalized drug screening. Autologous iPSCs could be generated from somatic cells of a patient and subsequently differentiated down to a specific lineage, then transplanted back into that same patient without any risk of immune rejection; this strategy has been successfully validated in animal models. In general terms, iPSC technology opens up an interesting pathway toward direct derivation of patient-specific pluripotent stem cells applied in regenerative medicine with personalization.
What are the uses of iPSC disease modeling in modern medicine?
It is important to study disease mechanisms in order to develop effective therapies. One strategy being pursued involves modeling familial and sporadic disease processes with induced pluripotent stem cells at both cell and organism levels. Several investigators have generated iPSC lines from unaffected controls as well as patients with amyotrophic lateral sclerosis, Alzheimer’s disease, frontotemporal dementia, cardiac hypertrophy, Parkinson’s disease, and sickle cell disease. Significantly sporadic forms of these diseases have been modeled by cell lines with knockout mutations in genes related to the unfolded protein response.
Additional efforts have used iPSCs carrying multiple disease-related genetic alterations. To date, these iPSC lines have been utilized in defining variant-specific phenotypes, examining the impact of neuronal cell-glial cell interactions on disease progression, and assessing the contribution of epigenetic reprogramming to cellular aging and cell-sensitive responses. Other applications include whole-organism modeling in zebrafish. Disease models are gaining from transcriptomic and proteomic data of real patients while focused CRISPR-Cas9 libraries are promising tools for the exploration of pathogenic mechanisms specifically concerning the genes involved in risk factor penetrance as well as those modifying phenotypic expressivity.
How does iPSC drug development speed up new therapies?
It is no simple feat to transmute increasing insights about diseases made possible by the use of iPSC-derived models into actual treatments for those very diseases; however, it can be done—using iPSC-derived models—to discover and optimize new drug compounds that would act on a particular process of disease. Faculty members are now applying their expertise in iPSC-derived human neurons toward the discovery of novel drugs for treatment-resistant epilepsy through high-content imaging platform development for screening drugs on human cortical neurons carrying an epilepsy-associated ion channel mutation. This opens another front in using iPSCs for drug discovery.
Another ongoing project is looking to accelerate drug development for the common neural tube defect spina bifida. Currently, the accepted treatment for spina bifida is surgical intervention in uterus, but this is risky for both mother and baby. The research team has developed a novel chemical cocktail that can induce neural tube closure in mouse embryos and are investigating whether it could lead to a safer avenue of drug intervention in pregnancy for mothers carrying babies with spina bifida
What challenges exist in translating iPSC work to care?
The efforts at generating cures and treatments with iPSCs have gained much interest in clinics as well as research laboratories. A plethora of human diseases and conditions can be studied, modeled, and treated with iPSCs differentiated into human somatic cells. Regenerative medicine, disease modeling, drug development, toxicology, genetic disease, and cancer are some areas of interest. However, a myriad of challenges must be navigated by researchers before these applications become available routinely to patients.
Regenerative medicine using iPSCs has great promise but equally great challenges in the path to clinical use. Some complications are similar to those concerning ESCs, especially the issues of graft versus host disease and teratoma formation. The risks associated with patient-specific iPSC therapy may seem trivial—for instance, implanting iPSC-derived cells in immune-deficient mouse recipients—but they become much more critical when one considers the potential application for neural repair in a fully immune-competent organism as a multi-step procedure involving cell propagation, expansion, and maturation. Other complications arise from the fact that this is a developing field. The clinical use of iPSCs requires containment of an enormous number of variables and unknowns: reprogramming method, type of somatic cell used to initiate the culture, conditions and time taken for culturing in vitro, differentiation protocol along with growth factors used, site where cells will be implanted into the patient’s body, and even what kind of person will be receiving them.
What could be the future of stem cell research with iPSCs?
New research tools and advances in the greater stem cell field can trigger developments in stem cell science. Catalytic developments can take place in related, then-unexpected subfields such as biomarker detection for neurological disorders and eventually come back to affect the iPSC field after first being applied to other cells. Adaptive investigation of new discoveries may even eventually affect the use of iPSC-derived cardiomyocytes in drug safety testing. The field itself is always changing, thus making it hard to predict what lies ahead. A great many goals have been pursued with iPSCs and their differentiated derivatives by this community, with certain priority areas coming into increasing focus.
In an effort to provide immediate benefits to patients, universities are leading an iPSC-directed heart regeneration trial in humans despite prior mixed success in animal models. In an attempt to explore new paths that leverage the unique qualities of iPSCs, researchers are trying to activate that endogenous reparative response which iPSCs elicit when transplanted but have not yet recapitulated. Several groups are using iPSCs for small-molecule therapy development. High-throughput phenotyping indicates disease mechanisms; scale-up drug discovery and screening using pluripotency disease models lead to an avalanche of candidates. This work is showing more uses for iPSCs than anyone thought possible when this technology was first developed. It is based on advances already made but will go on down paths that nobody has even begun to think about yet.